Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CC-11050 in Healthy Adults
NCT04139226Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dovramilast in Tuberculosis (TB), erythema nodosum leprosum (ENL) and cutaneous lupus erythematosus (CLE), sponsored by Amgen. Primary endpoint: Adverse Events. Started Aug 2019; status: completed.
02
Drugs
dovramilast
03
Conditions
Tuberculosis (TB)erythema nodosum leprosum (ENL)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT04139226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139226.